Mechanisms of antidiabetic drugs and cholesterol efflux: A clinical perspective.

Ali Ahmadi, Mariam Bagheri Ekta, Amirhossein Sahebkar

Drug discovery today 2022 Jun

filter terms:

Reverse cholesterol transport (RCT) is a physiological process that reduces excess cholesterol in the body. Cholesterol efflux (CE), an important step in RCT, is mainly mediated by ATP-binding cassette transporters A1 and G1 and has a significant role in atheroprotection. Moreover, impairments in CE can lead to the development of diabetes and fatty liver disease. In this review, we summarize the possible effects of hypoglycemic agents on CE and how this might influence atherosclerosis and dyslipidemia-related pathologies. Newer antidiabetic agents could have significant potential for targeting CE and preventing or alleviating atherosclerosis, obesity, and liver steatosis, and simultaneously improving insulin secretion. However, more research is warranted to interpret the clinical relevance of these data. Copyright © 2022 Elsevier Ltd. All rights reserved.

Citation

Ali Ahmadi, Mariam Bagheri Ekta, Amirhossein Sahebkar. Mechanisms of antidiabetic drugs and cholesterol efflux: A clinical perspective. Drug discovery today. 2022 Jun;27(6):1679-1688